Ensysce Biosciences, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $5.1M | $5.2M | $2.2M | $2.5M | $3.5M | $3.9M |
| Cost of Revenue | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| Operating Expenses | ||||||
| Research & Development | $10.4M | $7.2M | $7.6M | $19.8M | $4.7M | $4.4M |
| SG&A Expense | $4.9M | $4.7M | $5.4M | $6.9M | $18.7M | $1.2M |
| Operating Income | $-10.2M | $-6.7M | $-10.7M | $-24.2M | $-19.9M | $-1.6M |
| Operating Margin | -202.1% | -129.2% | -480.5% | -959.9% | -562.7% | -41.0% |
| Interest Expense | $6.4K | $8.8K | $353.9K | $109.5K | $1.3M | $995.5K |
| Pretax Income | — | — | — | — | — | $4.6M |
| Income Tax Expense | — | — | — | — | — | $244.5K |
| Net Income | $-10.2M | $-8.0M | $-10.6M | $-24.2M | $-29.1M | $4.3M |
| Net Margin | -200.8% | -153.3% | -476.4% | -959.3% | -825.4% | 109.7% |
| EPS (Basic) | $-3.98 | $-11.45 | $-17.60 | $-34.86 | $-7.41 | $0.00 |
| EPS (Diluted) | $-3.98 | $-11.45 | $-17.60 | $-34.86 | $-0.37 | $0.00 |
| Shares Outstanding (Basic) | 2.6M | 697.7K | 603.7K | 719.7K | 4.0M | 63.1M |
| Shares Outstanding (Diluted) | 2.6M | 697.7K | 603.7K | 719.7K | 80.7M | 66.0M |
| Dividends Per Share | — | — | — | — | — | — |